Evidence map›Paper›PMID 28512387›Full record

ReviewMediators of inflammation2017

Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.

So Young Yoo, Narayanasamy Badrinath, Hyun Young Woo, Jeong Heo

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Mediators of inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Immunotherapy for advanced or recurrent hepatocellular carcinoma.World journal of gastrointestinal oncology · 2023
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

So Young YooBIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0001-8875-9289
Narayanasamy BadrinathBIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0003-4203-4180
Hyun Young WooDepartment of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Yangsan 50612, Republic of Korea.
Jeong HeoDepartment of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Yangsan 50612, Republic of Korea.ORCID 0000-0003-0961-7851
Pusan National University Hospital · KRPusan National University Yangsan Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularHumansImmunotherapyLiver NeoplasmsNiacinamideOncolytic VirotherapyOncolytic VirusesPhenylurea CompoundsSorafenibAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenib

Identifiers

PMID28512387
PMCPMC5415860
OpenAlexW2606084795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.